BMS and Johnson & Johnson battle over novel CAR-T cell therapy in Europe

robot
Abstract generation in progress

BMS and Johnson & Johnson are engaged in a legal battle over their respective CAR-T cell therapies for multiple myeloma in Europe. BMS, through its acquired subsidiary 2seventy bio, has filed a patent infringement lawsuit at the UPC against Johnson & Johnson and Legend Biotech concerning their drug Carvykti. Concurrently, Johnson & Johnson is challenging the patent at the UK High Court and the European Patent Office.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)